U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C40H43N7O7S
Molecular Weight 765.877
Optical Activity UNSPECIFIED
Defined Stereocenters 5 / 5
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PARITAPREVIR

SMILES

CC1=NC=C(N=C1)C(=O)N[C@H]2CCCCCC=C[C@@H]3C[C@]3(NC(=O)[C@@H]4C[C@H](CN4C2=O)OC5=NC6=CC=CC=C6C7=CC=CC=C57)C(=O)NS(=O)(=O)C8CC8

InChI

InChIKey=UAUIUKWPKRJZJV-QPLHLKROSA-N
InChI=1S/C40H43N7O7S/c1-24-21-42-33(22-41-24)35(48)43-32-16-6-4-2-3-5-11-25-20-40(25,39(51)46-55(52,53)27-17-18-27)45-36(49)34-19-26(23-47(34)38(32)50)54-37-30-14-8-7-12-28(30)29-13-9-10-15-31(29)44-37/h5,7-15,21-22,25-27,32,34H,2-4,6,16-20,23H2,1H3,(H,43,48)(H,45,49)(H,46,51)/b11-5-/t25-,26-,32+,34+,40-/m1/s1

HIDE SMILES / InChI

Molecular Formula C40H43N7O7S
Molecular Weight 765.877
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry
Defined Stereocenters 5 / 5
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Paritaprevir is a potent inhibitor of the NS3/4A protease that rapidly and consistently suppresses HCV. Paritaprevir is metabolized by the Cytochrome P450 isoform 3A (CYP3A); therefore, ritonavir was used concurrently to increase plasma concentrations and to prolong the half-life of this agent allowing for once-daily dosing. Several antiviral regimens combining paritaprevir with other agents have shown impressive results, tolerable side effects, and importantly, provided support of ‘all-oral’ interferon-free regimens against HCV. Paritaprevir monotherapy is discontinued now but paritaprevir is used as a component of Viekira Pak and Technivie for the treatment of patients with genotype 1 chronic hepatitis C virus (HCV) infection.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
TECHNIVIE
PubMed

PubMed

TitleDatePubMed
ABT-450 combined with ritonavir, in addition to ABT-333 and ribavirin: a race for an interferon-free regimen to cure HCV infection.
2013 Oct
ABT-450: a novel protease inhibitor for the treatment of hepatitis C virus infection.
2014
New antiviral agents for the treatment of hepatitis C: ABT-450.
2014 Apr
In vitro and in vivo antiviral activity and resistance profile of the hepatitis C virus NS3/4A protease inhibitor ABT-450.
2015 Feb
Interferon-free therapy for hepatitis C: The hurdles amid a golden era.
2015 Sep
Efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with ribavirin for the treatment of HCV genotype 1b compensated cirrhosis in patients aged 70 years or older.
2017 Dec
Ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin for treatment of chronic hepatitis C 1 genotype in the Republic of Belarus.
2017 Sep
Safety and Efficacy of Ombitasvir, Paritaprevir With Ritonavir ± Dasabuvir With or Without Ribavirin in Patients With Human Immunodeficiency Virus-1 and Hepatitis C Virus Genotype 1 or Genotype 4 Coinfection: TURQUOISE-I Part 2.
2017 Summer
Paritaprevir/Ritonavir/Ombitasvir Plus Dasabuvir Therapy-Related Severe Anemia.
2018 Apr
Twelve weeks of ombitasvir/paritaprevir/r and dasabuvir without ribavirin is effective and safe in the treatment of patients with HCV genotype 1b infection and compensated cirrhosis: results from a real-world cohort study.
2018 Mar
Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin.
2018 Sep
Patents

Sample Use Guides

In Vivo Use Guide
50, 100 and 200 mg daily for 3 days (each dose in combination with 100 mg ribavirin).
Route of Administration: Oral
In Vitro Use Guide
To determine the breadth of coverage in genotype 1, the activity of Paritaprevir against chimeric replicons containing sequences derived from 11 genotype 1a- and 9 genotype 1b-infected patients was characterized. EC50s ranged from 0.43 to 1.87 nM against the genotype 1a isolates and from 0.033 to 0.087 nM against the genotype 1b isolates, indicating that Paritaprevir can inhibit NS3 proteases across a broad range of genotype 1 isolates.
Substance Class Chemical
Created
by admin
on Mon Oct 21 19:47:39 UTC 2019
Edited
by admin
on Mon Oct 21 19:47:39 UTC 2019
Record UNII
OU2YM37K86
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PARITAPREVIR
DASH   INN   USAN   VANDF   WHO-DD  
INN   USAN  
Official Name English
ABT-450
Code English
PARITAPREVIR [INN]
Common Name English
VERUPREVIR ANHYDROUS
Common Name English
(2R,6S,12Z,13AS,14AR,16AS)-N-(CYCLOPROPYLSULFONYL)-6-(5-METHYLPYRAZIN-2-CARBOXAMIDO)-5,16-DIOXO-2-(PHENANTHRIDIN-6-YLOXY)-1,2,3,6,7,8,9,10,11,13A,14,15,16,16ATETRADECAHYDROCYCLOPROPA(E)PYRROLO(1,2-A)(1,4)DIAZACYCLOPENTADECINE-14A(5H)-CARBOXAMIDE
Systematic Name English
PARITAPREVIR [USAN]
Common Name English
VIEKIRAX COMPONENT PARITAPREVIR
Brand Name English
PARITAPREVIR [WHO-DD]
Common Name English
PARITAPREVIR COMPONENT OF VIEKIRAX
Brand Name English
PARITAPREVIR [VANDF]
Common Name English
VERUPREVIR
Common Name English
Classification Tree Code System Code
WHO-ATC J05AX67
Created by admin on Mon Oct 21 19:47:39 UTC 2019 , Edited by admin on Mon Oct 21 19:47:39 UTC 2019
NCI_THESAURUS C783
Created by admin on Mon Oct 21 19:47:39 UTC 2019 , Edited by admin on Mon Oct 21 19:47:39 UTC 2019
WHO-ATC J05AP53
Created by admin on Mon Oct 21 19:47:39 UTC 2019 , Edited by admin on Mon Oct 21 19:47:39 UTC 2019
NDF-RT N0000182639
Created by admin on Mon Oct 21 19:47:39 UTC 2019 , Edited by admin on Mon Oct 21 19:47:39 UTC 2019
FDA ORPHAN DRUG 509215
Created by admin on Mon Oct 21 19:47:39 UTC 2019 , Edited by admin on Mon Oct 21 19:47:39 UTC 2019
WHO-ATC J05AP52
Created by admin on Mon Oct 21 19:47:39 UTC 2019 , Edited by admin on Mon Oct 21 19:47:39 UTC 2019
FDA ORPHAN DRUG 484715
Created by admin on Mon Oct 21 19:47:39 UTC 2019 , Edited by admin on Mon Oct 21 19:47:39 UTC 2019
WHO-ATC J05AX66
Created by admin on Mon Oct 21 19:47:39 UTC 2019 , Edited by admin on Mon Oct 21 19:47:39 UTC 2019
EMA ASSESSMENT REPORTS VIEKIRAX (AUTHORIZED: HEPATITIS C, CHRONIC)
Created by admin on Mon Oct 21 19:47:39 UTC 2019 , Edited by admin on Mon Oct 21 19:47:39 UTC 2019
Code System Code Type Description
EVMPD
SUB166312
Created by admin on Mon Oct 21 19:47:39 UTC 2019 , Edited by admin on Mon Oct 21 19:47:39 UTC 2019
PRIMARY
INN
9739
Created by admin on Mon Oct 21 19:47:39 UTC 2019 , Edited by admin on Mon Oct 21 19:47:39 UTC 2019
PRIMARY
NDF-RT
N0000182638
Created by admin on Mon Oct 21 19:47:39 UTC 2019 , Edited by admin on Mon Oct 21 19:47:39 UTC 2019
PRIMARY HCV NS3/4A Protease Inhibitors [MoA]
NDF-RT
N0000190108
Created by admin on Mon Oct 21 19:47:39 UTC 2019 , Edited by admin on Mon Oct 21 19:47:39 UTC 2019
PRIMARY Organic Anion Transporting Polypeptide 1B3 Inhibitors [MoA]
NDF-RT
N0000190107
Created by admin on Mon Oct 21 19:47:39 UTC 2019 , Edited by admin on Mon Oct 21 19:47:39 UTC 2019
PRIMARY Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA]
EVMPD
SUB131077
Created by admin on Mon Oct 21 19:47:39 UTC 2019 , Edited by admin on Mon Oct 21 19:47:39 UTC 2019
PRIMARY
CAS
1216941-48-8
Created by admin on Mon Oct 21 19:47:39 UTC 2019 , Edited by admin on Mon Oct 21 19:47:39 UTC 2019
PRIMARY
NDF-RT
N0000191272
Created by admin on Mon Oct 21 19:47:39 UTC 2019 , Edited by admin on Mon Oct 21 19:47:39 UTC 2019
PRIMARY UGT1A1 Inhibitors [MoA]
PUBCHEM
45110509
Created by admin on Mon Oct 21 19:47:39 UTC 2019 , Edited by admin on Mon Oct 21 19:47:39 UTC 2019
PRIMARY
DRUG BANK
DB09297
Created by admin on Mon Oct 21 19:47:39 UTC 2019 , Edited by admin on Mon Oct 21 19:47:39 UTC 2019
PRIMARY
NDF-RT
N0000185503
Created by admin on Mon Oct 21 19:47:39 UTC 2019 , Edited by admin on Mon Oct 21 19:47:39 UTC 2019
PRIMARY P-Glycoprotein Inhibitors [MoA]
ChEMBL
CHEMBL3391662
Created by admin on Mon Oct 21 19:47:39 UTC 2019 , Edited by admin on Mon Oct 21 19:47:39 UTC 2019
PRIMARY
RXCUI
1597373
Created by admin on Mon Oct 21 19:47:39 UTC 2019 , Edited by admin on Mon Oct 21 19:47:39 UTC 2019
PRIMARY RxNorm
WIKIPEDIA
Paritaprevir
Created by admin on Mon Oct 21 19:47:39 UTC 2019 , Edited by admin on Mon Oct 21 19:47:39 UTC 2019
PRIMARY
NCI_THESAURUS
C123879
Created by admin on Mon Oct 21 19:47:39 UTC 2019 , Edited by admin on Mon Oct 21 19:47:39 UTC 2019
PRIMARY
CAS
1221573-85-8
Created by admin on Mon Oct 21 19:47:39 UTC 2019 , Edited by admin on Mon Oct 21 19:47:39 UTC 2019
NO STRUCTURE GIVEN
NDF-RT
N0000190113
Created by admin on Mon Oct 21 19:47:39 UTC 2019 , Edited by admin on Mon Oct 21 19:47:39 UTC 2019
PRIMARY Breast Cancer Resistance Protein Inhibitors [MoA]
LactMed
1216941-48-8
Created by admin on Mon Oct 21 19:47:39 UTC 2019 , Edited by admin on Mon Oct 21 19:47:39 UTC 2019
PRIMARY
Related Record Type Details
EXCRETED UNCHANGED
FECAL
BINDER->LIGAND
BINDING
METABOLIC ENZYME -> SUBSTRATE
MAJOR
TRANSPORTER -> SUBSTRATE
EXCRETED UNCHANGED
URINE
METABOLIC ENZYME -> SUBSTRATE
Related Record Type Details
METABOLITE -> PARENT
MAJOR
URINE
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
blood-to-plasma ratio PHARMACOKINETIC
Tmax PHARMACOKINETIC